RxDoctor Payments Data

Raymond Poliakin, MD

Obstetrics & Gynecology · Thousand Oaks, CANPI 1386707636

Payments from drug & device makers

$36,536in general payments, 2019–2025

Across 443 payments — averaging $82.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$32K
  • AbbVie$831
  • Therapeuticsmd, Inc.$391
  • Avion Pharmaceuticals$388
  • Mayne Pharma Commercial LLC$299
  • AMAG Pharmaceuticals, Inc.$191
  • plus $2K from 24 others
$290in research payments, 2019–2025

Across 1 payment — averaging $290.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$290

What the payments were for

  • Food & beverage$4,65295%
  • Education$2355%
  • Gifts$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$36,536 in reported general payments places this provider in the 95th percentile of 3,784 obstetrics & gynecology providers in California.

See all obstetrics & gynecology providers in California

Medicare billing

Part B allowed, 2024
$55,466
Medicare patients
298
Services billed
970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated21$9,837
Estradiol180$5,695
PremproEstrogen,con/M-Progest Acet13$3,092
Estradiol (Twice Weekly)Estradiol39$2,995
YuvafemEstradiol17$2,524
ValacyclovirValacyclovir Hcl40$2,153
ProgesteroneProgesterone, Micronized66$1,565
Estradiol (Once Weekly)Estradiol17$1,401
DottiEstradiol16$1,235
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet24$718
Medroxyprogesterone Acetate41$485
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip13$284
Ibandronate Sodium15$241
Cefdinir12$240
Alendronate Sodium14$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin, Prempro$32,335$12,92934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,784 obstetrics & gynecology providers in California.

Other obstetrics & gynecology in Thousand Oaks

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →